GLP-1 drugs enter psychiatry, curbing antipsychotic weight gain while raising new questions about addiction, mood, eating disorders, and culture.
Publication|Articles|November 5, 2026
Our Continued Evolution
Author(s)Mike Hennessy Jr
Discover expanded psychiatry coverage with new podcasts, interactive digital issues, and event reporting—we are your always-on media hub delivering fresh insights year-round.
Advertisement
It has been a big year for psychiatry. To meet the field’s continued growth, we as a brand must evolve. In the past 11 months, we have launched new podcasts, such as “
We are here to be your go-to for live psychiatry media, 24/7, 365 days a year. But through this season of change, we will remain the source you know and love.
What else would you like to see from us? Share with us at
Mike Hennessy Jr
Chairman and CEO, MJH Life Sciences
Advertisement
Related to this article
Miss Golden Corner 2026 discusses the South Carolina campus naloxone law she helped start and her push to reduce addiction stigma in rural communities.
Explore the urgent legal, ethical, and clinical challenges in emergency psychiatry, share cases and tips, and contribute to Psychiatric Times’ November series.
Alkermes launches a phase 2 trial of oral orexin-2 agonist ALKS 7290 to boost antidepressant response in major depressive disorder, assessing safety and symptom relief.
BCG vaccination curbs tau tangles in mice by boosting microglial cleanup, fueling hopes for human trials to reduce dementia risk.
GLP-1 weight-loss drugs may worsen eating disorders or mask symptoms; experts urge careful screening, specialist referral, and monitoring before, during, and after use.
Sabirnetug phase 2 Alzheimer trial misses cognitive endpoint despite lowering amyloid, prompting Acumen to halt development and open-label extension plans.
Check out our pipeline updates from October!
Advertisement
Advertisement
Trending on Psychiatric Times
1
The Ozempic Dilemma: Promises and Pitfalls in Psychiatry
2
Brain Trust: Bessel van der Kolk, MD, on Complex PTSD, Attachment, and the Limits of Pharmacotherapy
3
Podcast: Campus Naloxone Access and Destigmatizing Substance Use Disorders
4
Artificial Intelligence in Psychiatric Clinical Trials: Opportunities and Limitations
5